AUS
NZ
UK
CA
USA
IND
Viking Therapeutics (NASDAQ:VKTX), a clinical-stage biopharmaceutical company, is making significant strides in the development of a weight-loss drug that could shake up the highly competitive obesity medication market. While the company has multiple products in its pipeline, VK2735, an obesity treatment, is currently capturing the attention and optimism of many investors. Given the recent peaks in its share price, observers are eager to assess whether Viking can sustain its momentum and reach new heights.
VK2735 is being developed as an injectable treatment for obesity and has yielded promising results in preliminary studies. A Phase 2 clinical trial showed that the drug significantly reduced body weight from baseline after just 13 weeks of administration. Moreover, it has demonstrated a favorable safety and tolerability profile, bolstering confidence in its potential efficacy. With these encouraging results, Viking is preparing to advance VK2735 into Phase 3 trials. The company plans to hold an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) by the end of this year, marking a critical step in the drug's development pathway.
The demand for GLP-1 weight-loss drugs in the United States is soaring, driven by a limited number of approved options. Currently, Novo Nordisk's Wegovy is the frontrunner in this market, following its FDA approval for obesity in 2021. Wegovy, a higher-dose version of the diabetes medication Ozempic, continues to dominate, with sales increasing by 37% year over year in the most recent quarter. Compounding the competitive landscape, Eli Lilly has entered the fray with Zepbound, a weight-loss counterpart to its diabetes drug Mounjaro. With Eli Lilly's extensive resources and marketing prowess, Zepbound poses a formidable challenge to existing players.
Despite the competitive pressures, Viking’s decision to pursue VK2735 reflects a promising market opportunity. According to healthcare research firm IQVIA Holdings, global sales of obesity drugs reached approximately $24 billion last year, with optimistic projections estimating the market could expand to $100 billion by the early 2030s. In the months since, even higher forecasts of $150 billion have begun to circulate, underscoring the growth potential in this sector.
Attention in the biotech world will be keenly focused on Viking's upcoming discussions with the FDA and, crucially, the outcomes of the Phase 3 trials for VK2735. In addition to the injectable formulation, Viking is also developing an oral version of the medication, which could significantly enhance its appeal to patients who prefer non-injectable treatments. Preliminary results from a Phase 1 study of oral VK2735 have been promising, and the company aims to initiate Phase 2 testing by the start of 2025. Should it succeed, the oral formulation could provide a competitive edge over current injectable options like Wegovy and Zepbound.
While VK2735 is generating considerable excitement, it is important to note that Viking Therapeutics is not solely focused on weight loss. The company is also advancing its other drug candidates, including VK2809, which targets non-alcoholic steatohepatitis (NASH) and has shown success in a Phase 2b trial. Furthermore, VK0214 is in development for X-linked adrenoleukodystrophy (X-ALD), a rare neurodegenerative condition, and has recently completed enrollment for a Phase 1 study.
